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ABSTRACT
Peripheral blood progenitor cell (PBPC) harvests mobilized by granulocyte colony-stimulating factor (G-CSF)
contain more CD34 cells and provide more rapid engraftment than do bone marrow (BM) harvests. However,
some reports have suggested a higher risk of chronic graft-versus-host disease (GVHD), possibly because such
PBPC harvests contain approximately 10 times more T lymphocytes than do BM harvests. Some groups are
attempting to combine the faster engraftment of PBPCs with the lower incidence of GVHD observed after
BM transplantation by using G-CSF–primed BM conventionally harvested from iliac crests for allogenic
BM transplantation. We report the results of a pilot study of 38 allogeneic transplants using G-CSF–
stimulated BM from related donors, with a focus on the harvest composition, engraftment, and incidence
of acute and chronic GVHDs.
© 2006 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Bone marrow (BM) has been the accepted source
f hematopoietic cells for allogeneic transplantation.
owever, historical comparisons have shown that pe-
ipheral blood progenitor cell (PBPC) transplantation
obilized by granulocyte colony-stimulating factor
G-CSF) offers quicker neutrophil and platelet recov-
ry, apparently with less treatment-related toxicity
nd mortality [1-4]. This may be due in part to the
igher stem cell content of G-CSF–primed PBPCs.
-CSF may also activate quiescent progenitors and
asten their maturation, leading to faster engraftment
hrough qualitative changes in the cellular composi-
ion of the harvest [2]. However, some reports have
ndicated a higher rate of chronic graft-versus-host
isease (GVHD) in G-CSF–stimulated PBPC recipi-
nts, probably because such PBPC harvests contain
pproximately 1 log more T lymphocytes than do
onventional BM harvests [5-7]. Several groups have
xamined the use of G-CSF–primed BM for autolo- sous hematopoietic transplantation and reported
ranulocyte and platelet recovery times similar to
hose seen after blood stem cell transplantation [3]. A
ew teams have studied the use of G-CSF–primed BM
or allogeneic BM transplantation (BMT) and re-
orted faster neutrophil engraftment and similar
ransplant-related complications compared with con-
entional BMT [8-11].
We report the results of a pilot study of allogeneic
ransplantation using G-CSF–stimulated BM from re-
ated donors, with a focus on the harvest composition,
ngraftment, and incidence of acute and chronic
VHDs.
ETHODS
atients
Between January 2001 and March 2003, patients
ligible for BMT at our center were invited to partic-
pate in this study. With their written informed con-
ent and institutional review board approval, 38 pa-
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M. Ostronoff et al.730ients underwent G-CSF–stimulated HLA-matched
ibling BMT. The conditioning protocol depended on
iagnosis and disease status (Table 1).
Broad-spectrum antibiotics were administered
hen patients became neutropenic (absolute neutro-
hil count .5  109/L) until neutrophil recovery.
rradiated platelet transfusions were given if the plate-
et count was 20  109/L, and irradiated red blood
ells were transfused when the hemoglobin concen-
ration was 9 g/dL. Patients received G-CSF 5-10
g · kg1 · d1 subcutaneously until hematologic re-
overy.
GVHD prophylaxis included cyclosporine A
CSA) 2 mg · kg1 · d1 and methotrexate (MTX) 15
g/m2 on day 1 and 10 mg/m2 on days 3 and 6.
ycophenolate mofetil (MMF) 15 mg · kg1 · d1
as also given to 16 patients because of a new insti-
utional protocol started during this study period. For
onmalignant diseases, if GVHD was absent, CSA
as then tapered from day 210 until day 240, when the
rug was discontinued; for malignant diseases, CSA
as tapered from day 150 until day 180. MMF was
dministered from day 0 until day 120.
onors and Harvest
With their written informed consent, donors re-
eived 5 g · kg1 · d1 of G-CSF subcutaneously for
days before BM harvest (day 4 to day 0; Table 2).
ll donors were HLA-identical siblings. BM was col-
ected on the ﬁfth day from the posterior iliac crests
target volume, 10-15 mL/kg recipient body weight).
D34, CD3, and CD8 cells were counted by ﬂow
ytometry. No manipulations were performed on the
roduct, other than red blood cell or plasma depletion in
able 1. Preparatory Regimens According to Diagnosis and Disease
tatus*
Diagnosis
Preparatory
Regimen
Disease
Stage
hronic myeloid leukemia
(first chronic phase) BUS  LPAM† 16
cute myeloid leukemia
First CR BUS  LPAM† 3
Second CR 2
cute lymphoid leukemia
First CR FTBI  CTX‡ 4
Second CR 1
evere aplastic anemia BUS  CTX§ 9
aroxysmal nocturnal
hemoglobinuria BUS  LPAM† 1
yelodysplastic syndrome BUS  LPAM† 2
CR indicates complete remission; BUS, busulfan; LPAM, melpha-
lan; CTX, cyclophosphamide; FTBI, fractionated total body
irradiation.
BUS (16 mg/kg orally)  LPAM (140 mg/m2).
FTBI (1200 cGy)  CTX (120 mg/kg).
BUS (4 mg/kg orally)  CTX (200 mg/kg) [22].he event of ABO major discrepancy between donor and *atient, and BM was infused on day 0. This regimen of
ow- to moderate-dose, short-course G-CSF was used to
inimize exposure of normal donors to this growth
actor.
valuation
The date of neutrophil engraftment was the ﬁrst
f 3 consecutive days with an absolute neutrophil
ount .5  109/L. The date of platelet engraftment
as the ﬁrst of 7 consecutive days with a platelet count
20 109/L without transfusion. GVHD was graded
ccording to published criteria [12].
Descriptive statistics (median and range) were
sed to describe donor, recipient, and BM character-
stics. Times to neutrophil and platelet engraftment
nd BM cell counts were compared with published
istorical data [13-16].
ESULTS
onor and Graft Characteristics
Donors were 26 female and 12 male subjects, with
median age of 26 years (range, 1 to 54). The only
mmediate adverse effects of G-CSF injections were
ild arthralgia and bone pain, which were successfully
reated with paracetamol.
BM harvests contained a median of 3.8  106
D34 cells/kg recipient weight (range, .94 to 13.5) ,
1  106 CD3 lymphocytes/kg (range, 19 to 62.8),
nd 12.9  106 CD8 lymphocytes/kg (range, 8 to
0.2).
atients, Engraftment, and GVHD
The patients were 12 female and 26 male subjects,
ith a median age of 30 years (range, 3 to 53); 12
atients were 18 years old. Disease status was
hronic myeloid leukemia in the ﬁrst chronic phase in
6 cases; severe aplastic anemia in 9 cases; acute lym-
hoblastic leukemia in ﬁrst complete remission in 4
ases; acute myeloid leukemia in the ﬁrst complete
emission in 3 cases; acute myeloid leukemia in the
econd complete remission in 2 cases; myelodysplastic
yndrome in 2 cases; acute lymphoblastic leukemia
nd central nervous system relapse in 1 case; and
octurnal paroxysmal hemoglobinuria in 1 case. Eigh-
een patients had sex-matched donors and 20 had
able 2. Characteristics of Donors and Harvests*
ge, y 26 (1-54)
ale/female 12/26
emale donor/male recipient 17/38
D34/kg recipient weight 3.8  106 (0.94-13.5)
D3/kg recipient weight 31  106 (19-62.8)
D8/kg recipient weight 12.9  106 (8-30.2)Data are means (ranges).
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Allogenic G-CSF–Stimulated BMT 731ex-mismatched donors (female donor/male recipient
n 17 cases, 10 with previous pregnancies, and male
onor/female recipient in 3 cases; Table 3).
Median duration of follow up was 42 months.
edian time to neutrophil recovery was 12 days
range, 6 to 20) and median time to platelet recovery
as 21 days (range, 10 to 28). One patient developed
raft failure, probably owing to immunologic rejec-
ion (multiple previous transfusions, including from
er parents). Two patients died before engraftment
rom veno-occlusive disease. These 3 patients were
ot assessable for acute GVHD because of early death.
cute GVHD grade2 occurred in 13 of the remain-
ng 35 patients (37.1%) patients and grade 3/4 acute
VHD occurred in 4 patients (11.4%); the gastroin-
estinal tract and liver were the main target sites (84%
nd 38% of cases, respectively). Chronic GVHD (al-
ays mild) occurred in 10 of the 29 patients (34.4%)
ho survived 100 days after transplantation. There
ere no differences in the incidence of acute or
hronic GVHD between the group that received
SA/MTX and the group that received CSA/MTX/
MF for GVHD prophylaxis. The overall 100-day
ortality rate was 23.6% (9 deaths). Causes of death
ere veno-occlusive disease in 2 cases; infection in 4
ases; acute GVHD in 1 case; relapse in 1 case; and
emorrhagic cystitis in 1 case. Infectious deaths were
ainly due to nosocomial infections and included
able 3. Characteristics of Patients and Outcomes*
ge, y 26 (3-53)
ale/female 26/12
eutrophil engraftment, d 12 (6-20)
latelet engraftment, d 21 (10-28)
RM at day 100 23.6%
verall survival 65.7%
Data are means (ranges). TRM indicates therapy-related mortality.
able 4. Comparison of Stem Cell Sources*
Characteristic Allogenic P
D34 cells  106/kg recipient weight 7.3 (1-29.8
D3 cells  106/kg recipient weight 279 (143-7
eutrophil engraftment, d 16 (11-29
14 (10-40
11 (9-20)
latelet engraftment, d 13 (5-41)
18 (13-68
13 (9-35)
GVHD (grade 2) 64%†
40%‡
48%§
GVHD 46%†
65%‡
aGVHD indicates acute GVHD; cGVHD, chronic GVHD.
Adapted from Bensinger et al [13].
Adapted from Champlin et al [14].
Adapted from Bishop et al [15] who used G-CSF after transplant
Adapted from Schriber et al [16] who used G-CSF after transplantationlebsiella pneumoniae, which was susceptible only to
mipenem, in 1 case, multidrug-resistant Pseudomonas
eruginosa in 2 cases, and Aspergillosis in 1 case. Ther-
py-related mortality was 23.6%; causes of death were
hose included in the overall 100-day mortality in
ddition to 1 death due to chronic GVHD, which
ccurred at 1 year. Overall survival and relapse-free
urvival were 65.7% and 63.1%, respectively.
ISCUSSION
We treated 38 patients with G-CSF–primed allo-
eneic BMT in this single-center study. The results
re compared in Table 4 with published historical data
n conventional BMT and PBPC transplantation us-
ng or not using MTX for GVHD prophylaxis and
-CSF after transplantation. We found that time for
eutrophil engraftment after G-CSF–stimulated BMT
as similar to that reported after PBPC transplantation.
ime to platelet recovery, however, was similar to that
bserved after conventional BMT. CD34 cell counts
ere similar to those obtained in unstimulated BM and
n PBPC harvests. There were 2 cases of CD34 counts
10  106/kg and both were observed with children as
onors. CD3 cell counts were similar to those observed
n the conventional BMT setting. The incidence of acute
nd chronic GVHD was compatible with that observed
n other settings. The relatively slow platelet reconstitu-
ion observed in the present study conﬁrms that of a
ecent report based on data from the International Bone
arrow Transplant Registry [17].
Couban et al [10] reported a single-arm study of
9 patients who received G-CSF–primed BM. Gran-
locyte and platelet recovery was faster in the G-CSF
roup than in historical controls, but this did not
mprove secondary endpoints such as the length of
ospital stay. Isola et al [8] compared 17 patients who
Allogenic BM G-CSF–Primed BM
2.4 (0.8-10.4)† 3.8 (0.94-13.5)
23.8 (5.4-347)† 31 (19-62.8)
21 (13-36)† 12 (6-20)
19 (11-35)‡
16 (14-27)
19 (7-74)† 21 (10-28)
25 (12-87)‡
27 (17-110)
57%† 37.1%
35%‡
8%
35%† 34.4%
53%‡
d CSA/MTX for GVHD prophylaxis.BPC
)†
88)†
)†
)‡
§
†
)‡
§
ation an
and CSA/MTX for GVHD prophylaxis.
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M. Ostronoff et al.732eceived G-CSF–primed BMT with controls who re-
eived conventional BMT and associated more rapid
eutrophil recovery with a shorter hospital stay, al-
hough the incidence of GVHD or death was not
ncreased. Platelet engraftment was not improved.
In a Chinese study, Shuquan et al [11] compared
arvest content, engraftment, and GVHD between
atients who received stimulated BM and those who
eceived conventional BMT. They found that stimu-
ated BM contained a larger number of granulocyte-
acrophage colony-forming units and CD34 cells,
nd that patients who received this harvest demon-
trated faster engraftment. The incidence of chronic
VHD and relapse did not differ between groups.
Serody et al [9] reported a nonrandomized study
f patients who received G-CSF–mobilized PBPC or
-CSF–stimulated BM and found a 1-log lower
-cell dose in the group that received BM. Granulo-
yte recovery was similar in the 2 groups, but there
as a trend toward faster platelet recovery in the
BPC group. Patients who received primed BM had
igniﬁcantly less chronic GVHD. A randomized study
y Morton et al [18] compared outcomes after stem
ell transplantation in patients who received PBSC or
M from donors treated with G-CSF. They found
hat, compared with recipients of G-CSF–primed
M, patients undergoing PBSC transplantation were
ore likely to develop severe acute GVHD refractory
o prednisone and chronic GVHD, with a need for
rolonged immunosuppressive therapy to control
ymptoms.
In these studies, the dose of G-CSF for BM prim-
ng ranged from 3 to 12 g · kg1 · d1 and the
ength of G-CSF treatment ranged from 2 to 7 days.
In a recent study, Ringden et al [19] of the Euro-
ean Group for Blood and Marrow Transplantation
eported a retrospective analysis of the use of G-CSF
fter allogeneic stem cell transplantation and found
shortening of neutropenia but a lengthening of
hrombocytopenia. Importantly, when BM was the
ource of stem cells, G-CSF after transplantation in-
reased incidences of acute and chronic GVHDs and
reatment-related mortality. These adverse effects of
-CSF were not seen in recipients of PBPC [19].
hether these ﬁndings also apply to G-CSF–primed
MT remains to be seen.
In the present study, G-CSF was administered
ntil hematologic recovery, which may have contrib-
ted to the faster recovery of neutrophil and the rel-
tively slow recovery of platelets [15].
Because of a new institutional protocol started
uring the study period, MMF was given to 16 pa-
ients. A few phase II clinical studies have been con-
ucted on the combination of MMF and CSA for
VHD prophylaxis, and it is not completely under-
tood if MMF affects engraftment kinetics. A recent
tudy found that median time to engraftment in pa-ients who received MMF and CSA for GVHD pro-
hylaxis was similar to that in patients who received
VHD prophylaxis with CSA and MTX [20].
Another possible use of G-CSF priming is in non-
yeloablative allogeneic BMT, for which a high stem
ell dose is needed to compensate for less intense
nduction therapy, as shown in animal models [21].
he lower incidence of chronic GVHD associated
ith the higher CD34 cell counts obtained in
-CSF–primed BMT could be beneﬁcial for this
ode of transplantation.
It is important to note that this study was per-
ormed in a developing country, where infection dur-
ng neutropenia remains a major problem, and means
f accelerating neutrophil recovery are therefore of
reat interest.
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